Monday, June 30 – A growing body of evidence shows that GLP-1 drugs benefit cardiovascular health. Image Credit: Healthline/Munro/Getty Images

GLP-1 medications like Ozempic and Wegovy help protect heart health, but stopping the medications may reduce the protective effects.

Some research suggests that GLP-1s containing tirzepatide (Zepbound, Mounjaro) may help lower the risk of further complications in people with cardiovascular disease.

Other research suggests that GLP-1s may help reduce thromboembolic events, such as deep vein thrombosis (DVT), in people with obesity and autoimmune diseases.

Monday, June 30 – Scientists at The Wistar Institute have shown that a single injection of a small, circular piece of genetic instruction can produce weight loss and blood glucose control in murine models that lasts up to 10 times as long as incretin-mimicking drugs like Ozempic and Wegovy. If shown to be successful in clinical trials, this new method of delivery could eliminate the need for repeated dosing, which currently limits patient access and adherence to these therapies.

Monday, June 30 – (MedPage Today) — At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates…

Monday, June 30 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic or Wegovy, have revolutionized type 2 diabetes and weight-loss management, but they have also led to some unfortunate outcomes. A recent study in JAMA Psychiatry has raised concerns that GLP-1 medications may be misused by people with eating disorders. These are serious mental health conditions in which thoughts about food, body weight and body shape become overwhelming, leading to harmful eating behaviors and an intense drive to control food intake. Although concerns about weight or appearance are common, eating disorders go far beyond these everyday worries.

Saturday, June 27 – GLP-1 drugs can provide benefits that may boost an athlete’s performance, but do these medications give them the competitive edge? Getty Images/The Good Brigade

Debates are emerging over whether GLP-1 drugs boost athletic performance.

However, experts say the loss of lean mass associated with using these drugs may cancel out any competitive advantages.

Saturday, June 27 – (MedPage Today) — Use of GLP-1 receptor agonists was associated with a higher risk of smell and taste disturbances among adults with type 2 diabetes, an analysis of electronic health record (EHR) data suggested.
Compared with matched controls…

Saturday, June 27 – “‘Mommy has to take shots to conform to what other people think will look better.'”View Entire Post ›

Saturday, June 27 – A report about unusual access to an experimental obesity drug has raised interest in the condition pulmonary hypertension.

Friday, June 26 – Some GLP-1 users report changes in their taste and smell, according to a new study. Tatsiana Volkava/Getty Images

Researchers report that GLP-1 drugs used to treat type 2 diabetes may impair a person’s sense of taste and smell.

Experts say taste and smell dysfunction doesn’t appear to be a common side effect of GLP-1s, which are widely prescribed for weight loss.

Friday, June 26 – As the use of GLP-1 medications for weight loss surges, so do calls to U.S. poison control centers, according to a new study.

Friday, June 26 – (MedPage Today) — In patients with inflammatory bowel disease (IBD), the use of GLP-1 receptor agonists was linked to a lower risk of colorectal cancer (CRC), according to a retrospective study presented at the American Society of Clinical Oncology…

Friday, June 26 – As people age, they often develop chronic conditions, many of which need to be managed with multiple prescription medications. While medications are important for disease management, polypharmacy poses an increased risk for harmful side effects and contraindications.

THURSDAY, June 25, 2026 — As the use of GLP-1 medications for weight loss surges, so do calls to U.S. poison control centers, according to a new study.
A team led by Jordan Miller of the University of Texas at San Antonio analyzed reports…

Friday, June 26 – A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to a 12% reduction in body weight after 36 weeks, according to a randomized phase II clinical trial published in Nature Medicine.

Thursday, June 25 – An estimated 14 million Medicare Part D recipients could obtain Wegovy, Foundayo, and Zepbound for $50 per month. Johner Images/Getty Images

Federal officials announced the launch of a Medicare GLP-1 Bridge pilot program that reduces the cost of certain GLP-1 medications prescribed for weight loss.

Under the program, Wegovy, Foundayo, and Zepbound KwikPens will cost $50 per month for eligible participants enrolled in Medicare Part D plans.

The program begins on July 1 and continues through Dec. 31, 2027.

Some Medicare recipients will soon be able to purchase a limited number of GLP-1 weight loss drugs at a guaranteed price of $50 per month.

Thursday, June 25 – People are getting more care and using lots of GLP-1 drugs, fueling a sharp increase in health care spending.

Drug buyers want a New York federal judge to preserve proposed class claims accusing Novo Nordisk of paying Teva to delay generic competition with its Victoza GLP-1 drug, arguing that whatever the underlying deal was, no generic version materialized when it could have.  

Thursday, June 25 – (MedPage Today) — Use and misuse of GLP-1 receptor agonists were common in people with eating disorders, interim results of an ongoing cross-sectional study suggested.
Among over 400 people with eating disorders, 32.1% said they have used GLP…

Eli Lilly and Co. posted $19.8 billion in first-quarter 2026 revenue, driven by tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. The Indianapolis-based drugmaker is channeling cash flow from these blockbuster GLP-1 drugs into an aggressive dealmaking campaign — about $25.1 billion across 10 announced acquisitions so far this year and more than $26 billion in other closed deals.

Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according to top-line results.

Wednesday, June 24 – Giving an individual special access to an experimental obesity drug is highly unusual.

Wednesday, June 24 – The “triple-G” weight loss drug, Pfizer’s lung cancer trial results, and more biotech news from The Readout

Wednesday, June 24 – Eli Lilly’s weight-loss franchise—including the tirzepatide products Mounjaro and Zepbound, and the weight-loss pill Foundayo—is projected to account for nearly half of the total sales of the top 10 drugs in 2032.

Tuesday, June 23 – Wegovy, Zepbound named first choice for obesity treatment in new guidelines

Tuesday, June 23 – Researchers say that GLP-1 drugs containing tirzepatide (Zepbound, Mounjaro) may lead to greater weight loss. Image Credit: Tatsiana Volkava/Getty Images

A meta-analysis found that one type of GLP-1 medication may be more effective than others. 

The analysis showed that GLP-1s containing tirzepatide (Zepbound, Mounjaro) helped people lose more weight than those containing semaglutide (Ozempic, Wegovy). 

Liraglutide (Saxenda) had the lowest weight loss percentage among users. 

The success of tirzepatide may be due to its dual mechanism, which targets multiple receptors.

Tuesday, June 23 – (MedPage Today) — At the American Diabetes Association annual meeting, updated phase II data from the VESPER program showed that patients who achieved weight loss with a weekly dose of the ultra-long-acting investigational GLP-1 agonist berobenatide…

Tuesday, June 23 – For many people, the thought of a tasty burger or a cold pint of beer conjures a vivid mental image and drives behavior. This link between thinking and doing serves a clear function—it motivates us to get the necessities of life.

Monday. June 22 – The obesity treatment landscape is changing fast, with GLP-1 drugs opening the door to more effective care than ever before. Experts now envision a future where medications, minimally invasive procedures, surgery, and precision medicine work together to deliver better long-term results.

Saturday, June 20 – GLP-1s may help reduce impulsivity, alcohol intake, and violent behaviors in adults. Image Credit: munro/gettyimages

A recent study found that GLP-1 medications like Ozempic and Wegovy may help lower impulsive and violent behaviors.

The researchers noted that higher impulsivity and alcohol use were significantly associated with violent behavior overall, but were weaker among those using GLP-1s.

Saturday, June 20 – GLP-1 weight loss drugs like Ozempic are linked to cosmetic concerns, including sagging earlobes, deflated breasts and flatter buttocks, surgeons say.

FRIDAY, June 19, 2026 — Ozempic doesn’t only help people lose weight, but might also protect against broken bones, a new study says.
People with type 2 diabetes treated with semaglutide (Ozempic/Wegovy) had a 15% lower risk of bone…

Friday, June 19 – GLP-1 drugs show early promise for improving fertility in males and females

Friday, June 19 – Mayim Bialik recently shared the “nightmare” experience she had after using a GLP-1 drug. Image Credit: Laurent Koffel/Getty Images

Actor Mayim Bialik has shared her “nightmare” experience that left her with weeks of side effects after one GLP-1 medication dose. 

Bialik said her symptoms included severe diarrhea and full-body aches. 

She revealed that she tried a GLP-1 after her doctor suggested it may help with her autoimmune disease symptoms.

Friday, June 19 – Setting a weight loss goal may yield greater success with GLP-1 drugs like Zepbound. Image Credit: Crispin la valiente/GettyImages

A recent study found that people who set personal weight loss targets may achieve greater results with GLP-1 medications. 

People using tirzepatide (Zepbound or Mounjaro) saw more weight loss if they set goals or had previously tried structured diet plans.

Friday, June 19 – What’s next for GLP-1 weight loss drugs? Alex Hogan explores on the new episode of STATus Report. Watch now.

Friday, June 19 – (MedPage Today) — The FDA cleared Wave Neuroscience’s biomarker-guided neuromodulation system (MeRT) to treat post-traumatic stress disorder (PTSD), the company announced.
Gastrointestinal interoception was disrupted across multiple domains in…

WEDNESDAY, June 17, 2026 — Adults with obesity initiating glucagon-like peptide-1 receptor agonist (GLP-1RA) medications have a significant decrease in their physical activity, according to a study presented at ENDO 2026, the annual meeting of the…

WEDNESDAY, June 17, 2026 — More than half of adults with type 2 diabetes mellitus (T2DM) who discontinue glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reinitiate within one year, according to a study presented at ENDO 2026, the annual…

Wednesday, June 17 – Using GLP-1s may increase your risk of heat-related illnesses. Image Credit: Nora Carol Photography/Getty Images

GLP-1 medications may increase heat-related risks by suppressing thirst and reducing fluid intake.

Thirst reduction may lead to severe dehydration and even kidney damage. 

GLP-1 drugs may also lower blood pressure in some people, potentially leading to other heat-related issues in people with low blood pressure.

A Rutgers study suggests GLP-1 drugs such as Ozempic and Wegovy may weaken the link between impulsive tendencies and violent behavior. The surprising finding hints that these medications could affect how people act on impulses, though researchers stress that cause and effect have not been proven.